Endocrine therapy is the main treatment for advanced prostate cancer, and currently the most applied drug depot and anti-androgen therapy. The most commonly used drugs are Norelide or Daphylline, which mainly compete with GNRH to bind to GNRH receptors, thus inhibiting testosterone secretion and achieving the effect of de-escalation. The side effect of drug depot is a transient increase in testosterone at the beginning of the drug, which can promote the progression of the disease in some patients. There is a new endocrine therapy drug for prostate cancer that can inhibit GNRH receptors to achieve the drug depot effect. A multi-center clinical program for patients with advanced prostate cancer in China is currently being conducted in several hospitals in China and has been approved by the State Food and Drug Administration. If you meet all the conditions of the program and sign the informed consent form to participate, you can receive the relevant free tests and medication, and follow the arrangements of the medical staff for regular observation and follow-up guidance.